Nkarta (NKTX) reported second-quarter 2026 financial results, including a net loss of $40.4 million, or $0.54 per basic and diluted share. The company had cash, cash equivalents, restricted cash and investments in marketable securities of $243.2 million as of June 30, 2026.
Nkarta said enrollment continues in Ntrust-1 and Ntrust-2 for NKX019 across autoimmune disease indications at the 4 billion cell dose level. Initial clinical data from both trials are expected to be presented at a medical conference in 2026.
- Research and development expenses were $29.0 million for the second quarter of 2026.
- General and administrative expenses were $14.1 million for the quarter.
- Patients are being dosed at 4 billion cells per dose across three doses, totaling 12 billion cells.
- Outpatient dosing is underway through community-based sites.
- Nkarta expects its current cash and cash equivalents to fund its operating plan into 2029.
$NKTX Insider Trading Activity
$NKTX insiders have traded $NKTX stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $NKTX stock by insiders over the last 6 months:
- PAUL J HASTINGS (Chief Executive Officer) sold 1,776 shares for an estimated $4,812
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$NKTX Hedge Fund Activity
We have seen 67 institutional investors add shares of $NKTX stock to their portfolio, and 40 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. added 1,791,739 shares (+39.7%) to their portfolio in Q2 2026, for an estimated $5,070,621
- TWO SIGMA INVESTMENTS, LP added 1,075,394 shares (+110.6%) to their portfolio in Q1 2026, for an estimated $2,269,081
- ACADIAN ASSET MANAGEMENT LLC added 567,689 shares (+82.0%) to their portfolio in Q1 2026, for an estimated $1,197,823
- CITADEL ADVISORS LLC added 438,761 shares (+32.6%) to their portfolio in Q1 2026, for an estimated $925,785
- PANAGORA ASSET MANAGEMENT INC added 299,039 shares (+105.2%) to their portfolio in Q2 2026, for an estimated $846,280
- AQR CAPITAL MANAGEMENT LLC added 276,734 shares (+86.8%) to their portfolio in Q1 2026, for an estimated $583,908
- NUVEEN, LLC added 255,115 shares (+133.8%) to their portfolio in Q1 2026, for an estimated $538,292
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
